NMT posts encouraging early data on PFO implant BioSTAR
This article was originally published in Clinica
NMT Medical says that positive findings are now available to support the use of its bioabsorbable cardiac defect repair technology, BioSTAR. The minimally-invasive, catheter-based implant is currently being investigated in a multi-centred clinical trial, called BEST (BioSTAR Evaluation Study), as a means of closing a patent foramen ovale (PFO).
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.